Fate Therapeutics, Inc. (FATE)
2.11
+0.02
(+0.96%)
USD |
NASDAQ |
Oct 23, 16:00
2.11
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Price to Book Value : 1.605 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.605 |
| October 22, 2026 | 1.590 |
| October 21, 2026 | 1.574 |
| October 20, 2026 | 1.567 |
| October 19, 2026 | 1.415 |
| October 16, 2026 | 1.361 |
| October 15, 2026 | 1.464 |
| October 14, 2026 | 1.476 |
| October 13, 2026 | 1.521 |
| October 12, 2026 | 1.62 |
| October 09, 2026 | 1.658 |
| October 08, 2026 | 1.62 |
| October 07, 2026 | 1.635 |
| October 06, 2026 | 1.742 |
| October 05, 2026 | 1.848 |
| October 02, 2026 | 1.764 |
| October 01, 2026 | 1.749 |
| September 30, 2026 | 1.802 |
| September 29, 2026 | 1.810 |
| September 28, 2026 | 1.810 |
| September 25, 2026 | 1.787 |
| September 24, 2026 | 1.772 |
| September 23, 2026 | 1.848 |
| September 22, 2026 | 1.962 |
| September 21, 2026 | 1.924 |
| Date | Value |
|---|---|
| September 18, 2026 | 1.924 |
| September 17, 2026 | 1.917 |
| September 16, 2026 | 1.856 |
| September 15, 2026 | 1.787 |
| September 14, 2026 | 1.780 |
| September 11, 2026 | 1.757 |
| September 10, 2026 | 1.772 |
| September 09, 2026 | 1.856 |
| September 08, 2026 | 1.901 |
| September 04, 2026 | 1.886 |
| September 03, 2026 | 1.840 |
| September 02, 2026 | 1.863 |
| September 01, 2026 | 1.848 |
| August 31, 2026 | 1.818 |
| August 28, 2026 | 1.848 |
| August 27, 2026 | 1.932 |
| August 26, 2026 | 1.955 |
| August 25, 2026 | 1.939 |
| August 24, 2026 | 1.856 |
| August 21, 2026 | 1.772 |
| August 20, 2026 | 1.863 |
| August 19, 2026 | 2.015 |
| August 18, 2026 | 1.947 |
| August 17, 2026 | 1.993 |
| August 14, 2026 | 1.955 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.32 |
| Anika Therapeutics, Inc. | 2.088 |
| BioCryst Pharmaceuticals, Inc. | -- |
| Imunon, Inc. | 1.376 |
Price to Book Value Related Metrics
| PS Ratio | 38.90 |
| Price | 2.11 |
| Earnings Yield | -49.91% |
| Market Cap | 246.22M |